Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBIO 
Mustang Bio Inc (MBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.91% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.19M USD | Price to earnings Ratio 0.78 | 1Y Target Price 10 |
Price to earnings Ratio 0.78 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 2.23 | 52 Weeks Range 0.95 - 18.50 | Updated Date 08/29/2025 |
52 Weeks Range 0.95 - 18.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.99 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate - | Actual -0.19 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.89% | Return on Equity (TTM) -1191.31% |
Valuation
Trailing PE 0.78 | Forward PE - | Enterprise Value -1471748 | Price to Sales(TTM) - |
Enterprise Value -1471748 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 6394260 | Shares Floating 6192467 |
Shares Outstanding 6394260 | Shares Floating 6192467 | ||
Percent Insiders 3.16 | Percent Institutions 3.18 |
Upturn AI SWOT
Mustang Bio Inc
Company Overview
History and Background
Mustang Bio, Inc. is a biopharmaceutical company focused on translating medical breakthroughs in cellular immunotherapy into potentially curative therapies for hematologic cancers, solid tumors and rare genetic diseases. Founded in 2015, it leverages the research of City of Hope and Fred Hutchinson Cancer Research Center.
Core Business Areas
- Cellular Immunotherapy: Developing and commercializing CAR-T cell therapies targeting various cancers and rare genetic diseases.
- MB-107 (Lentiviral Gene Therapy): Gene therapy to treat X-linked severe combined immunodeficiency (XSCID) in infants.
Leadership and Structure
Manuel Litchman, M.D., is the President and CEO. The company operates with a management team overseeing clinical development, research, and manufacturing.
Top Products and Market Share
Key Offerings
- MB-107 (Lentiviral Gene Therapy): Gene therapy candidate for XSCID. Currently in clinical trials. Competitors include Orchard Therapeutics (OTL) and potentially other gene therapy developers targeting XSCID. Market share unavailable as it is not yet approved.
- CAR-T cell therapies: CAR-T therapies targeting CD19-positive B-cell lymphomas and other hematologic malignancies. In clinical trials. Competitors include Novartis (Kymriah), Gilead (Yescarta), and Bristol Myers Squibb (Breyanzi). Market share unavailable as it is not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth, particularly in cellular immunotherapy and gene therapy. Driven by technological advancements and unmet medical needs.
Positioning
Mustang Bio is positioned as a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies. Its competitive advantage lies in its partnerships with leading research institutions.
Total Addressable Market (TAM)
The total addressable market for cell and gene therapies is estimated to reach billions of dollars. Mustang Bio aims to capture a portion of this market with its pipeline of therapies.
Upturn SWOT Analysis
Strengths
- Strong research collaborations with City of Hope and Fred Hutchinson
- Promising pipeline of cell and gene therapy candidates
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
Opportunities
- Potential for FDA approval of MB-107 and CAR-T therapies
- Expansion of pipeline through new research collaborations
- Increasing demand for cell and gene therapies
Threats
- Clinical trial failures
- Competition from other biopharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- NOVN
- GILD
- BMY
- OTL
Competitive Landscape
Mustang Bio faces intense competition in the cell and gene therapy space. Its competitive advantage lies in its specific targets and research collaborations, but it needs to navigate clinical and regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial advancements and partnerships. As a clinical-stage company, revenue generation is not significant.
Future Projections: Future projections are dependent on clinical trial success and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Focus on advancing MB-107 and CAR-T therapies through clinical trials, and exploring new research collaborations.
Summary
Mustang Bio is a clinical-stage company with potential in cell and gene therapy. Its strong research partnerships offer a solid foundation, but its success hinges on positive clinical trial outcomes and regulatory approvals. High cash burn and competition remain significant challenges. If the company can make good progress in phase 2 and phase 3 trials, the company has potential for FDA approval.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data may be delayed or inaccurate. Investing in biopharmaceutical companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mustang Bio Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2017-08-22 | President, CEO, Interim CFO & Director Dr. Manuel Litchman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.mustangbio.com |
Full time employees 6 | Website https://www.mustangbio.com | ||
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.